Stabilization of a progressive hemangioblastoma under treatment with thalidomide

Journal of Neuro-Oncology

Volumn 66, Issue 3, 2004, Pages 295-299

  Piribauer, Maria ^a   Czech, Thomas ^a   Dieckmann, Karin ^b   Birner, Peter ^b   Hainfellner, Johannes A ^b   Prayer, Daniela ^a   Fazeny Dörner, Barbara ^a   Weinländer, Geor ^a   Marosi, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiangiogenic; Hemangioblastoma; Hippel Lindau; Thalidomide

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; SEMAXANIB; THALIDOMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DEATH; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GAIT DISORDER; HEADACHE; HEMANGIOBLASTOMA; HUMAN; LEGIONNAIRE DISEASE; NAUSEA; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PATIENT MOBILITY; PNEUMONIA; QUADRIPLEGIA; SPINAL CORD METASTASIS; SPINAL CORD SURGERY; STOMACH CANCER; STOMACH SURGERY; SYMPTOM; VON HIPPEL LINDAU DISEASE; WHEELCHAIR;

ANGIOGENESIS INHIBITORS; CEREBELLAR NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEMANGIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME;

EID: 1342265868     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000014493.88402.dc     Document Type: Article

References (26)

1. Richard S, David P, Marsot-Dupuch K: Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev 23: 1-22, 2000
2. Gläsker S, Bender B, Apel T: The impact of molecular genetic analysis of the VHL gene in patients with hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatr 67: 758-762, 1999
3. Niemelä M, Lemeta S, Summanen P: Long-term prognosis of hemangioblastoma of the CNS: Impact of von Hippel-Lindau Disease. Acta Neurochir 141: 1147-1156, 1999
4. Spetzger U, Bertanlanffy H, Huffmann B: Hemangioblastomas of the spinal cord and the brainstem: Diagnostic and therapeutic features. Neurosurg Rev 19: 147-151, 1996
5. Neumann H, Eggert H, Weigel K: Hemangioblastomas of the central nervous system. J Neurosurg 70: 24-30, 1989
6. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997
7. Dredge K, Dagleish AG, Mariott JB: Recent developments in antiangiogenesis therapy. Expert Opin Biol Ther 2: 953-966, 2002
8. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002
9. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906-3927, 2002
10. Iyer CG, Languillonn J, Ramanujam K, Tarabini-Castellani TG, De Las Aguas JT, Bechelli LM: WHO coordinated short term double blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 45: 719-732, 1971
11. Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26: 351-362, 2000
12. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1993
13. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Clin Exp Ophtalmol 236: 461-466, 1998
14. Keifer JA, Guttridge DC, Ashburner BP, Baldwin J: Inhibition of NF-KappaB activity by thalidomide through suppression of 1kappaB-kinase activity. J Biol Chem 276: 22382-22387, 2001
15. Peuckmann V, Fisch M, Bruera E: Potential novel uses of thalidomide: Focus on palliative care. Drugs 60: 273-292, 2000
16. Schindl M, Birner P, Obermair A, Kiesel L, Wenzl R: Increased microvessel density in adenomyosis uteri. Fertil Steril 75: 131-135, 2001
17. Xu L, Fidler IJ: Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res 60: 4610-4616, 2000
18. König J, Tolnay E, Wiethege T, Müller K: Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435: 8-12, 1999
19. Flamme I, Krieg M, Plate H: Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 153: 25-29, 1998
20. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsens M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996
21. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228, 1999
22. Lee SH, Schloss DJ, Swain JL: Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J Biol Chem 275: 33679-33687, 2000
23. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18: 5356-5362, 1999
24. Niemelä M, Mäenpää H, Salven P, Summanen P, Poussa K, Laatikainen L, Jääskeläinen J, Joensuu H: Interferon α-2a therapy in 18 hemangioblastomas. Clin Cancer Res 7: 510-516, 2001
25. Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, Muller JB, Folkman J: Successful antiangiogenic therapy of giant cell angioblastoma with interferon α 2B: Report of 2 cases. Pediatrics 109: E37, 2002
26. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah Kaelin WG Jr: Rapid and durable recovery of visual function in a patient with von Hippel Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU 5418. Ophtalmology 109: 1745-1751, 2002